

Private Equity Investments in Physician Practices in Maryland


Yashaswini Singh, PhD, MPA

Erin C. Fuse Brown, JD, MPH

Maryland Health Care Commission


January 16, 2025

Rapid changes to physician organizations




A growing share of physicians are affiliated with PE firms nationally

Percentage of acquired physicians by type, 2019 - 2023




Trends in private equity (PE) penetration at the physician level in the US among 10 physician specialties, 2012-21



<https://www.aha.org/system/files/media/file/2023/06/Private-Equity-and-Health-Insurers-Acquire-More-Physicians-than-Hospitals-Infographic.pdf>



Abdelhadi, Ola, et al. "Private Equity-Acquired Physician Practices And Market Penetration Increased Substantially, 2012-21: Study examines private equity-acquired physician practices and market penetration." *Health Affairs* 43.3 (2024): 354-362.

What to expect from PE



Early evidence suggests that PE increases prices and utilization, also affects workforce composition

PE penetration across 6 office-based specialties, 2019



From: Singh, Y., Zhu, J. M., Polsky, D., & Song, Z. (2022, April). Geographic variation in private equity penetration across select office-based physician specialties in the US. *In JAMA health forum* (Vol. 3, No. 4, pp. e220825-e220825). American Medical Association.

- Nationally, PE acquisitions concentrated in FL, TX, AZ, Northeast (Singh et al., 2022)
- PE increases health care spending by increasing prices by 10–26% and service utilization (Singh et al., 2022, La Forgia et al., 2022, Braun et al., 2021)
- PE changes workforce composition by increasing hiring of physician assistants and nurse practitioners, increasing physician turnover (Singh et al., 2025, Bruch et al., 2023)
- PE has mixed effects on quality (Gupta et al., 2024, Kannan et al., 2024, Cerullo et al., 2022, Braun et al., 2021)

Concerns over PE have prompted policy attention but state-specific evidence is lacking


For Release

Federal Trade Commission, the Department of Justice and the Department of Health and Human Services Launch Cross-Government Inquiry on Impact of Corporate Greed in Health Care

Agencies seek info on transactions, including non-reportable deals, that may harm patients' health, workers' safety, quality of care, and affordability

- Concerns over PE in health care prompted a Request for Information from the Federal Trade Commission, Department of Justice, and Department of Health and Human Services and congressional investigations
- State-specific studies are sparse, reinforcing a need for more state-specific evidence to inform policymakers about the extent of PE penetration in the market
- The Maryland General Assembly passed legislation in 2024 (SB 1182/HB 1388) directing MHCC to study the evolving role of PE in the Maryland health care economy.

Study Overview: Private Equity Activity in Physician Practices in Maryland











Data and methods

- **Data sources**
 - Pitchbook data + manual verification
 - Medicare Data on Provider Practice and Specialty (MD-PPAS)
 - Network participation data from Maryland Medical Care Data Base
 - Data on participation in value-based programs provided by MHCC
 - American Community Survey (ACS) and Census data
- **Private Equity Penetration:** share of physicians that were affiliated with PE firms
 - Assigned physicians a ZIP code based on the ZIP code where a physician derived the plurality of Medicare fee-for-service claims in 2021

Limitations

- Underestimate PE penetration
 - MD-PPAS data available only through 2021
 - No data on certain specialties (e.g., emergency medicine, dental)
 - No data on certain providers (e.g., advanced practice providers)
- Analysis does not include other for-profit entities
- No systematic data on PE exits
 - Assume entity is PE-affiliated if it is ever PE-affiliated
- Lack of data on PE heterogeneity
- Cross-sectional data precludes determination of causality


PE penetration in Maryland increased from 1.8% (2014) to 15.5% (2021) across all physician specialties



PE penetration in Maryland is **higher than national estimates**

Physician Specialty	PE penetration in Maryland (2021)	Estimates of national PE penetration (Abdelhadi, et al., 2021)
Oncology	8%	4%
Orthopedics	9%	4%
Cardiology	15%	2%
Gastroenterology	17%	14%
Ophthalmology	25%	6%
Primary care	27%	2%
Dermatology	36%	11%
Urology	63%	8%
All specialties (average)	15%	--

PE penetration in Maryland is concentrated in certain regions




Over half of all physicians seen by residents of Prince George's County were PE affiliated in 2021


Seven rural counties had no PE penetration

PE penetration was greater in diverse communities

PE-affiliated physicians had **higher in-network participation in commercial and MA plans**



PE-affiliated PCPs had higher participation in the Maryland Primary Care Program






Summary

- **PE is part of a broader trend of corporate consolidation of physician practices**
- **Growing share of physicians in Maryland are PE-affiliated (15% in 2021)**
 - Variation across specialties and geographic regions
- **PE-affiliated physicians had higher rates of in-network participation**
 - PE acquisitions increase prices by 10–26% (Singh et al., 2022, La Forgia et al., 2022, Braun et al., 2021)
 - PE-affiliated practices deploy out-of-network billing (Cooper et al., 2020, Adler et al., 2023)
- **PE-affiliated physicians had higher rates of participation in value-based programs**
 - Value-based payment may create a need for capital
- **Policy challenge: balance need for capital investment by physician practices with protections for patients and the clinical workforce**

State Policy Options to Address Corporate Consolidation of Health Care Entities

From NASHP Model Law¹: *Addressing Corporatization of Health Care, Consolidation, Closures*

	Policy Approach	Policy Concerns
	Health Care Transaction Oversight Authority (NASHP Model Part I)	Consolidation, costs, closures, sale-leasebacks
	Strengthening the Prohibition on Corporate Practice of Medicine, Banning physician noncompetes, nondisparagement agreements (NASHP Model Part II)	Professional autonomy, workforce effects, interference with clinical decision-making
	Ownership Transparency (NASHP Model Part III)	Opacity, lack of accountability

¹ <https://nashp.org/a-model-act-for-state-oversight-of-proposed-health-care-mergers/>

Policy 1: Enhanced Transaction Oversight

Policy Concern

Traditional antitrust tools can be inadequate to address novel forms of health care consolidation, including private equity and other corporate investment

Response

Strengthen oversight authority over health care transactions in **two primary ways**

1. Expanding the Oversight Authority:

- Require **prior notice** of material transactions
- Expand **review** authority
- Enable authority to **block or impose conditions** upon the transaction without a court order

2. Expanding role of state health agencies: vest another state health entity (in addition to the state attorney general) with the authority to review and report on a proposed transaction's broader health care market impact.



NASHP Model Part I: Review of Proposed Material Change Transactions

NASHP released updated health care transaction oversight model in July 2024

Expands scope of entities covered

Private equity, management services orgs (MSOs), Real Estate Investment Trusts (REITs), payers, staffing companies

Expands types of transactions covered

Sale-leasebacks, MSO agreements, serial transactions going back 5 years, JVs, closures of key facilities or services, staffing agreements

Strengthens enforcement authority

- AG enforcement, penalties, injunctive relief
- State health agency enforcement
- Ongoing monitoring of transactions

NASHP Model Part II: Strengthening CPOM Laws

Add or clarify CPOM prohibition in statute

- Prohibit unlicensed lay-entities from owning, employing, or controlling medical practices
- Prohibit any unlicensed lay-entities from interfering with clinical decisions

Regulate Friendly PC/MSO structure (does not ban MSOs)

- Restrict dual compensation/control of PC and MSO
- Require that licensed professionals maintain ultimate control over clinical and business decisions in contracts with MSOs
- Enumerate types of clinical and business decisions that implicate CPOM
- Ban or limit gag-clauses (non-disparagement agreements)

Protections for employed physicians (e.g., by hospitals or other exempted entities)

- Ban or limit gag-clauses
- Noninterference with clinical decisions

Multiple routes of enforcement: AG, administrative agency, private actions

- Private enforcement (by aggrieved employee or competitor) can supplement administrative enforcement, whistleblower as “private AG”

Policy 3: Transparency of Ownership/Control

Response

- Require all existing health care entities to **report information** on owners, controlling entities, business structure, including the ultimate owners or controlling parent, subsidiaries, entities under common control, and any management services organizations
- Require all health care entities to **report any *changes* to ownership or control** (would also constitute a material change transaction for notice and review purposes)
- **Make this information available to the public**

NASHP Model Part III: Transparency of Ownership/Control

Part III of NASHP Model requires health care market participants to report ownership and control to the Dep't of Health or other designated state health care entity.

Applicability

Group practices, hospitals, health systems, nursing facilities, insurers, PBMs

Frequency

Annually and upon any material change notice (under Part I)

Required information to be reported

Name, location, TIN, NPI, EIN, CCN, NAIC, owners, significant equity investors, control entity, MSO, corporate org chart, subsidiaries, entities under common control, financial reports

Enforcement

DOH/Health Commission administrative penalties, audits

References

- Abdelhadi O, Fulton BD, Alexander L, Scheffler RM. Private Equity–Acquired Physician Practices And Market Penetration Increased Substantially, 2012–21. *Health Affairs*. 2024;43(3):354-362.
- Cooper Z, Scott Morton F, Shekita N. Surprise! Out-of-Network Billing for Emergency Care in the United States. *Journal of Political Economy*. 2020;128(9):3626-3677.
- Adler L, Milhaupt C, Valdez S. Measuring private equity penetration and consolidation in emergency medicine and anesthesiology. *Health Affairs Scholar*. 2023;1(1).
- Gupta A, Howell S, Yannelis C, Gupta A. Does Private Equity Investment in Healthcare Benefit Patients? Evidence from Nursing Homes. *SSRN Electronic Journal*. 2020.
- Braun RT, Jung HY, Casalino LP, Myslinski Z, Unruh MA. Association of Private Equity Investment in US Nursing Homes With the Quality and Cost of Care for Long-Stay Residents. *JAMA Health Forum*. 2021;2(11):e213817.
- Kannan S, Bruch JD, Song Z. Changes in Hospital Adverse Events and Patient Outcomes Associated With Private Equity Acquisition. *JAMA*. 2023;330(24):2365–2375.
- Cerullo M, Yang K, Joynt Maddox KE, McDevitt RC, Roberts JW, Offodile AC 2nd. Association Between Hospital Private Equity Acquisition and Outcomes of Acute Medical Conditions Among Medicare Beneficiaries. *JAMA Netw Open*. 2022;5(4):e229581.
- Singh Y, Song Z, Polsky D, Bruch JD, Zhu JM. Association of Private Equity Acquisition of Physician Practices With Changes in Health Care Spending and Utilization. *JAMA Health Forum*. 2022;3(9):e222886.
- Bruch, J. D., Foot, C., Singh, Y., Song, Z., Polsky, D., & Zhu, J. M. (2023). Workforce Composition In Private Equity–Acquired Versus Non– Private Equity–Acquired Physician Practices. *Health Affairs*, 42(1).
- Singh, Y., Zhu, J. M., Polsky, D., & Song, Z. (2022, April). Geographic variation in private equity penetration across select office-based physician specialties in the US. In *JAMA Health Forum* (Vol. 3, No. 4, pp. e220825-e220825). American Medical Association.
- Braun RT, Bond AM, Qian Y, Zhang M, Casalino LP. Private Equity In Dermatology: Effect On Price, Utilization, And Spending. *Health Affairs*. 2021;40(5):727-735.
- La Forgia, A., Bond, A. M., Braun, R. T., Yao, L. Z., Kjaer, K., Zhang, M., & Casalino, L. P. (2022). Association of physician management companies and private equity investment with commercial health care prices paid to anesthesia practitioners. *JAMA internal medicine*, 182(4), 396-404.
- Singh Y, Bejarano G, Torabzadeh H, Borkar D, Whaley C. Increase in Physician Turnover in Private Equity-Owned Physician Practices. *Health Aff (Millwood)*. Published online March 2025.
- Comprehensive Consolidation Model Addressing Transaction Oversight, Corporate Practice of Medicine and Transparency - NASHP*. National Academy for State Health Policy; 2024. Accessed January 10, 2025. <https://nashp.org/a-model-act-for-state-oversight-of-proposed-health-care-mergers/>
<https://www.aha.org/system/files/media/file/2023/06/Private-Equity-and-Health-Insurers-Acquire-More-Physicians-than-Hospitals-Infographic.pdf>
- PAI-Avalere Report on Physician Employment Trends and Acquisitions of Medical Practices: 2019-2023

CAHPR CENTER FOR ADVANCING
HEALTH POLICY
THROUGH RESEARCH



School *of*
Public Health
BROWN UNIVERSITY